Evolving therapies for non-alcoholic steatohepatitis

Author： Tilg Herbert   Moschen Alexander R  

Publisher： Informa Healthcare

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.9, Iss.6, 2014-06, pp. : 687-696

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Emerging drugs for non-alcoholic steatohepatitis

By Tomeno Wataru   Yoneda Masato   Imajo Kento   Ogawa Yuji   Kessoku Takaomi   Saito Satoru   Eguchi Yuichiro   Nakajima Atsushi  

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 3, 2013-09 ,pp. : 279-290

Informa Healthcare

Access to resources Recommend Favorite

Cyclophosphamide/dexamethasone: Non-alcoholic steatohepatitis: case report

By  

Reactions Weekly, Vol. 1, Iss. 1233, 2009-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Role of microRNAs in Non-Alcoholic Steatohepatitis

By  

Current Pharmaceutical Design, Vol. 16, Iss. 17, 2010-06 ,pp. : 1952-1957

Bentham Science Publishers

Access to resources Recommend Favorite

Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis

By Fisher Craig  

Archives of Toxicology, Vol. 82, Iss. 12, 2008-12 ,pp. : 959-964

Springer Publishing Company

Access to resources Recommend Favorite

Ketoprofen: Non-alcoholic fatty liver disease and steatohepatitis: case report

By  

Reactions Weekly, Vol. 1, Iss. 1348-1349, 2011-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite